The study covered in this summary was published in Research Square as a preprint and has not yet been peer reviewed. Nearly two thirds of Brazilian study participants with childhood-onset type 1 ...

The SELECT Trial has revealed the potential of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in combating kidney function decline among individuals with overweight or obesity and ...

A new study examines how a diabetes drug may protect the kidneys from aging.

The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular outcomes shows they have significant benefits in people with and without ...

Medications and extra fluid infusions can help protect your kidneys from damage during chemotherapy. More than one million people receive chemotherapy or radiation treatments for their cancer each ...

A molecule made by bacteria in the gut can hitch a ride to the kidneys, where it sets off a chain reaction of inflammation, scarring and fibrosis - a serious complication of diabetes and a leading ...

First patient successfully completes dosing at Toronto General Hospital St. Michael’s Hospital is expected to be the next Canadian clinical site activated Arch is looking for additional clinical sites ...

TORONTO, April 16, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that a research team from St. Michael’s Hospital, a ...